Cargando…
Metastatic sites and lesion numbers cooperated to predict efficacy of PD‐1 inhibitor‐based combination therapy for patients with metastatic colorectal cancer
BACKGROUND: Limited data have been used to evaluate the efficacy of immunotherapy in metastatic colorectal cancer (mCRC). Furthermore, potential markers that can be used to identify responding patients and to further improve efficacy have not been fully explored. METHODS AND RESULTS: In our study, w...
Autores principales: | Jiang, Weiqin, He, Yinjun, He, Wenguang, Zhang, Xiang, Chen, Nan, Li, Yandong, Zhong, Weixiang, Wu, Guosheng, Zhou, Xile, Hua, Hanju, Ye, Feng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278516/ https://www.ncbi.nlm.nih.gov/pubmed/37081776 http://dx.doi.org/10.1002/cam4.5959 |
Ejemplares similares
-
Soluble PD-L1: a potential dynamic predictive biomarker for immunotherapy in patients with proficient mismatch repair colorectal cancer
por: He, Yinjun, et al.
Publicado: (2023) -
Genomic and transcriptomic analysis of MSI-H colorectal cancer patients with targetable alterations identifies clinical implications for immunotherapy
por: Hua, Hanju, et al.
Publicado: (2023) -
Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy
por: Jiang, Weiqin, et al.
Publicado: (2021) -
Ideal number of target lesions per organ to measure in metastatic colorectal cancer
por: KIM, HYEONG SU, et al.
Publicado: (2014) -
Copy number and transcriptome alterations associated with metastatic lesion response to treatment in colorectal cancer
por: Gambaro, Karen, et al.
Publicado: (2021)